Antiviral Cytokines Induce Hepatic Expression of the Granzyme B Inhibitors, Proteinase Inhibitor 9 and Serine Proteinase Inhibitor 6
Overview
Affiliations
Expression of the granzyme B inhibitors, human proteinase inhibitor 9 (PI-9), or the murine orthologue, serine proteinase inhibitor 6 (SPI-6), confers resistance to CTL or NK killing by perforin- and granzyme-dependent effector mechanisms. In light of prior studies indicating that virally infected hepatocytes are selectively resistant to this CTL effector mechanism, the present studies investigated PI-9 and SPI-6 expression in hepatocytes and hepatoma cells in response to adenoviral infection and to cytokines produced during antiviral immune responses. Neither PI-9 nor SPI-6 expression was detected by immunoblotting in uninfected murine or human hepatocytes. Similarly, human Huh-7 hepatoma cells were found to express only very low levels of PI-9 relative to levels detected in perforin- and granzyme-resistant CTL or lymphokine-activated killer cells. Following in vivo adenoviral infection or in vitro culture with IFN-alphabeta or IFN-gamma, SPI-6 expression was induced in murine hepatocytes. Similarly, after culture with IFN-alpha, induction of PI-9 mRNA and protein expression was observed in human hepatocytes and Huh-7 cells. IFN-gamma and TNF-alpha also induced 4- to 10-fold higher levels of PI-9 mRNA expression in Huh-7 cells, whereas levels of mRNA encoding a related serine proteinase inhibitor, proteinase inhibitor 8, were unaffected by culture of Huh-7 cells with IFN-alpha, IFN-gamma, or TNF-alpha. These findings indicate that cytokines that promote antiviral cytopathic responses also regulate expression of the cytoprotective molecules, PI-9 and SPI-6, in hepatocytes that are potential targets of CTL and NK effector mechanisms.
Chen H, Lu Z, Ni X, Zhang H, Chen G, Wu X Immunotherapy. 2024; 16(14-15):975-985.
PMID: 39115961 PMC: 11486090. DOI: 10.1080/1750743X.2024.2383557.
The biological function of Serpinb9 and Serpinb9-based therapy.
Huang H, Mu Y, Li S Front Immunol. 2024; 15:1422113.
PMID: 38966643 PMC: 11222584. DOI: 10.3389/fimmu.2024.1422113.
: How Tumor Cells Defend Against the Siege Weapons of Cytotoxic T Lymphocytes.
McKenzie B, Khazen R, Valitutti S Front Immunol. 2022; 13:894306.
PMID: 35592329 PMC: 9110820. DOI: 10.3389/fimmu.2022.894306.
Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation.
Chen J, Cao Y, Markelc B, Kaeppler J, Vermeer J, Muschel R J Clin Invest. 2019; 129(10):4224-4238.
PMID: 31483286 PMC: 6763250. DOI: 10.1172/JCI127458.
Herrera-Uribe J, Jimenez-Marin A, Lacasta A, Monteagudo P, Pina-Pedrero S, Rodriguez F Vet Res. 2018; 49(1):90.
PMID: 30208957 PMC: 6134756. DOI: 10.1186/s13567-018-0585-z.